US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that it has entered into a strategic research collaboration with Isomorphic Labs, an AI-first drug design and development company, to discover small-molecule therapeutic candidates targeting an oncology indication.
The collaboration combines Isomorphic Labs' AI-driven drug design capabilities with Merck's proprietary data and drug discovery expertise.
Under the agreement, Isomorphic Labs will conduct computational predictions and deliver molecular designs using its proprietary drug design engine, IsoDDE, incorporating selected data sets provided by Merck. Merck will oversee preclinical and clinical development, manufacturing and commercialisation of any resulting products.
Isomorphic Labs will receive an upfront payment and be eligible for research, development, regulatory and commercial milestone payments, alongside tiered royalties on net sales. The agreement also grants Isomorphic Labs an option to co-fund development activities in exchange for higher royalty rates.
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial